Admedus is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Its focus is on investing in and developing next generation technologies with world class partners and acquiring strategic assets to grow product and service offerings.  The company has assets from research & development through clinical development and sales, marketing and distribution.

Admedus Ltd started its life as Allied Healthcare Group Ltd when its two parent companies Allied Medical Ltd and bioMD Ltd (ASX: BOD) merged in 2011.

In 2013, the Company changed its name from Allied Healthcare Group to Admedus Ltd as part of a global branding strategy, and acquired Verigen Australia Pty Ltd (now Admedus Biomanufacturing).

The original merger of Allied Healthcare Group Ltd and bioMD Ltd created a unique healthcare company with assets in research & development, products in advanced clinical trials ready for commercialisation, and a successful sales, marketing and medical device distribution business.

Since then, Admedus has continued to grow, expanding into new dynamic markets, investing in ground-breaking R&D and continuously refining our world-class manufacturing facility and processes.

Our clinically superior ADAPT® products have achieved nine years without calcification or degradation and our products are currently being used in more than 135 global centres in Australia, Europe, US, Canada, Singapore, Malaysia, India, Hong Kong and the Middle East.

In 2018, our focus is on investing in, and developing, next generation technologies with world class partners; acquiring strategic assets to grow product and service offerings and expanding revenues from our existing medical sales and distribution business.

We’re proud of our history and looking forward to our future.

Find out more about the unique benefits of our propriety ADAPT® technology.

Our Technology

Admedus is focused on developing, commercialising and distributing next-generation medical technologies with global potential.